Acelyrin Inc. (SLRN)
NASDAQ: SLRN
· Real-Time Price · USD
2.58
0.11 (4.45%)
At close: May 01, 2025, 3:59 PM
2.58
0.19%
After-hours: May 01, 2025, 05:02 PM EDT
4.45% (1D)
| Bid | 2.35 |
| Market Cap | 259.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -248.23M |
| EPS (ttm) | -2.5 |
| PE Ratio (ttm) | -1.03 |
| Forward PE | -1.39 |
| Analyst | Hold |
| Ask | 2.98 |
| Volume | 2,463,062 |
| Avg. Volume (20D) | 1,919,008 |
| Open | 2.50 |
| Previous Close | 2.47 |
| Day's Range | 2.48 - 2.65 |
| 52-Week Range | 1.84 - 7.25 |
| Beta | 1.14 |
About SLRN
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials...
Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2023
Employees 83
Stock Exchange NASDAQ
Ticker Symbol SLRN
Website https://www.acelyrin.com
Analyst Forecast
According to 5 analyst ratings, the average rating for SLRN stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 133.01% from the latest price.
Stock Forecasts2 months ago
+19.82%
ACELYRIN shares are trading higher after the compa...
Unlock content with
Pro Subscription
3 months ago
-36.96%
Acelyrin shares are trading lower after HC Wainwright & Co. cut its price target on the stock from $8 to $6.
